Geniko Nosokomeio Thessalonikis George Papanikolaou

The Respiratory Tract Diseases program at Geniko Nosokomeio Thessalonikis George Papanikolaou focuses on improving care for conditions such as asthma, chronic obstructive pulmonary disease, bronchiectasis, idiopathic pulmonary fibrosis, and pulmonary sarcoidosis.

• Severe asthma with eosinophilic phenotype
• Progression of chronic obstructive pulmonary disease
• Bronchiectasis with chronic Pseudomonas infection
• Therapeutic evaluation in idiopathic pulmonary fibrosis
• Imaging studies for active pulmonary sarcoidosis

Trials test novel inhaled agents, biologic therapies, and advanced diagnostics to reduce exacerbations and improve lung function.

Research on Non‑Small Cell Lung Cancer and small‑cell lung cancer aims to expand treatment options through targeted therapies, immunotherapy combinations, and adjuvant strategies after surgery.

• EGFR‑mutated NSCLC targeted agents
• KRAS G12C inhibitor versus chemotherapy
• PD‑L1 high NSCLC immunotherapy combos
• Adjuvant pembrolizumab post‑resection
• Bronchoscopic diagnostic advancements

The goal is to increase survival rates and assess safety of emerging drugs in advanced and early‑stage lung cancer.

The department investigates Acute Myeloid Leukemia, Multiple Myeloma, Myelofibrosis and related stem‑cell transplant complications, exploring cellular and targeted treatments.

• CAR‑T cell therapy for relapsed myeloma
• JAK inhibitor plus ruxolitinib in myelofibrosis
• Graft‑versus‑host disease prevention after HSCT
• Targeted agents for acute leukemias
• Novel regimens for mantle‑cell lymphoma

Studies seek to improve response durability and reduce transplant‑related toxicity.

Investigations into IgA nephropathy, Complement inhibition, and Atypical hemolytic uremic syndrome address proteinuria reduction and kidney protection.

• Ravulizumab for IgAN kidney function preservation
• Iptacopan in immune‑complex membranoproliferative GN
• Finerenone to slow CKD progression
• MK‑2060 for arteriovenous graft thrombosis prevention
• Complement blockade in paroxysmal nocturnal hemoglobinuria

The aim is to lower proteinuria, protect renal function, and improve vascular outcomes in high‑risk patients.

Programs targeting Arterial Hypertension, Heart failure with preserved ejection fraction, and Type 2 diabetes evaluate new drug combinations and inflammatory pathways.

• Fixed‑dose irbesartan/amlodipine efficacy
• Finerenone added to standard of care
• Inflammatory biomarkers in CKD with hypertension
• Triple bronchodilator therapy impact on cardiopulmonary outcomes in COPD
• Atherosclerotic disease management in end‑stage kidney disease

These trials aim to reduce cardiovascular events, improve blood pressure control, and mitigate renal inflammation.

The site also supports studies on Major Depressive Disorder, Schizophrenia, and seizure disorders, focusing on symptom relief and disease mechanisms.

• Iclepertin safety in schizophrenia
• Adjunctive therapy for treatment‑resistant depression
• Anti‑IL‑33 antibody for seizure reduction
• Neuroimaging biomarkers in pulmonary sarcoidosis affecting CNS
• Cognitive outcomes in chronic inflammatory disease

Objectives include improving quality of life, evaluating novel psychopharmacologic agents, and understanding neuro‑immune interactions.